Valion Bio, Inc.
VBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787740
No open-market purchases or sales by Valion Bio, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $205.6K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Valion Bio, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- 0 vs. Q1 2023
- Shares held
- 914.7K
- −513.2K (−35.9%) vs. Q1 2023
- Total value
- $96.3K
- −$119.3K (−55.3%) vs. Q1 2023
- New holders
- 3
- 3 more added
- Sold out
- 3
- 4 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $205.6K |
| Q1 2026 | 9 | $233.4K |
| Q4 2025 | 7 | $118.8K |
| Q3 2025 | 7 | $567.1K |
| Q2 2025 | 4 | $186.6K |
| Q1 2025 | 2 | $54 |
| Q4 2024 | 9 | $90.7K |
| Q3 2024 | 10 | $69.8K |
| Q2 2024 | 10 | $240.6K |
| Q1 2024 | 5 | $83.8K |
| Q4 2023 | 7 | $112.0K |
| Q3 2023 | 6 | $31.7K |
| Q2 2023 | 12 | $96.3K |
| Q1 2023 | 12 | $215.6K |
| Q4 2022 | 7 | $43.4K |
| Q3 2022 | 4 | $30.0K |
| Q2 2022 | 5 | $104.0K |
| Q1 2022 | 7 | $329.0K |
| Q4 2021 | 9 | $492.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Valion Bio, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 192 | $20 | 0.00% | +146+317.4% | Added |
| Advisor Group Holdings, Inc. | 8,900 | $941 | 0.00% | −5,700−39.0% | Reduced |
| Tower Research Capital LLC (TRC) | 11,054 | $1.17K | 0.00% | −21−0.2% | Reduced |
| HRT Financial LP | 26,944 | $2.00K | 0.00% | −98−0.4% | Reduced |
| One68 Global Capital, LLC | 19,100 | $2.02K | 0.01% | 00.0% | Unchanged |
| Cubist Systematic Strategies, LLC | 28,587 | $3.03K | 0.00% | +28,587 | New |
| Susquehanna International Group, LLP | 29,138 | $3.09K | 0.00% | +16,351+127.9% | Added |
| UBS Group AG | 29,619 | $3.14K | 0.00% | −103,241−77.7% | Reduced |
| Millennium Management LLC | 30,192 | $3.20K | 0.00% | +30,192 | New |
| Boothbay Fund Management, LLC | 34,200 | $3.62K | 0.00% | +4,200+14.0% | Added |
| Two Sigma Securities, LLC | 96,821 | $10.3K | 0.00% | +96,821 | New |
| Sheets Smith Wealth Management | 600,000 | $63.8K | 0.01% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −541,618−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −28,403−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −10,413−100.0% | Sold out |